ATYR:NASDAQ
aTyr Pharma Inc
0,46 $
arrow_downward
−5,28%(−0,025) 1D
0,46 $
arrow_upward
+1,01% (+0,0046)bedtimePo zaprtju
Zaprto: 9. sep., 16:00:01 GMT -4 · USD
search
Vsi simboli
1D
5D
1M
6M
TLDD
1L
5L
MAKS
| Simbol | Cena | Sprememba | Odstotna sprememba |
|---|
insights_autoGeneriranje najpomembnejših vpogledov za ATYR …
Odpri
0,48 $
Visoka
0,49 $
Nizka
0,45 $
Tržna kapitalizacija
44,74 mio.
Povprečni promet
622,59 tis.
Promet
829,82 tis.
52-tedenski najvišji tečaj
6,50 $
52-tedenski najnižji tečaj
0,40 $
Čisti dobiček na delnico
−0,62 $
Beta
0,53
Št. izdanih delnic
98,09 mio.
Št. zaposlenih
59
Odpri
0,48 $
Visoka
0,49 $
Nizka
0,45 $
Tržna kapitalizacija
44,74 mio.
Povprečni promet
622,59 tis.
Promet
829,82 tis.
52-tedenski najvišji tečaj
6,50 $
52-tedenski najnižji tečaj
0,40 $
Čisti dobiček na delnico
−0,62 $
Beta
0,53
Št. izdanih delnic
98,09 mio.
Št. zaposlenih
59
Novice
Iz spletnih virov in novičarskih partnerjev
Traders Union
·
pred 11 urami
ATyr Pharma shares drop almost 4% after persistent bearish momentum weighs on price
Profil
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla. Wikipedia
Vizitka: aTyr Pharma Inc